Trevi Therapeutics Inc
TRVI
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.55B
Close$
$0.13
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.29 |
| Beta | 1.07 |
| Outstanding Shares | 156,602,158 |
Return
| Return on Equity | -15.90% |
|---|---|
| Return on Assets | -15.46% |
| Return on Invested Capital | -17.69% |
Valuation & Multiples
| P/E Ratio | -53.17 |
|---|---|
| PEG | -119 |
| Price to Sales | - |
| Price to Book Ratio | 9.42 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -43.84 |
| Enterprise Value to Net Income | -49 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0336▼ 28.20% |
|---|---|
| Total Calls | 1,340,700▲ 45.24% |
| Total Puts | 45,100▼ 84.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 102.90%▲ 10.16% |
|---|---|
| Total Invested | $2.78B▲ 72.04% |
| Investors Holding | 221▲ 16.00% |
ESG Score
No data